Breakthrough T1D

“Form 990, part i, line 7b includes 512(a)(7) amounts that are not revenue and, therefore, not reported as such on form 990.”

“FORM 990, PAGE 6, PART VI, SECTION C, LINE 19 The organization makes its governing documents, conflict of interest policy and financial statements available to the public on its website: www.JDRF.org. The public may access copies of JDRF's W-9, annual reports, 990 tax returns, 501(c)(3) IRS letter, and audited financials, at the following link: www.jdrf.org/about/financials”

“PART VI, SECTION B, LINES 15a & 15b JDRF's Board of Directors charges a Talent and Compensation Committee to develop and recommend a compensation philosophy that applies to all employees of JDRF, including recommendations regarding the compensation and benefits of JDRF senior management for approval by the Board of Directors. The Committee works in collaboration with the President and CEO and the Chief People Officer and other senior staff personnel in the JDRF Human Resources Department to ensure that 1) the Foundation's talent strategy supports and is aligned with its overall organization strategies; 2) JDRF is in compliance with IRS guidelines for determining reasonableness in pay practices; and 3) overall compensation for JDRF's key executives is competitive and aligned with pay philosophy. To attract and retain top scientific and executive talent to advance its mission, the organization pays competitive and appropriate salaries as determined by analysis of reliable data and input from independent third-party consultants. The review of JDRF executive compensation and benefits under the procedures noted above is completed annually by an independent Compensation Committee, and the basis for their determination is documented contemporaneously in the minutes of the Committee's meetings, including most recently on June 20, 2019.”

“SECTION B, PART VI, QUESTION 11B JDRF has a rigorous standard approach to reviewing its 990. The Organization's Accounting Manager works with its outside tax professionals to prepare the return and all supporting schedules. The draft return is reviewed by a number of individuals, including JDRF's Chief Financial Officer and AVP, FINANCE and Finance, the Chief Executive Officer, other executives, its external senior tax advisor and others as necessary to ensure accuracy. Any questions and changes with respect to the draft return are addressed. Following this process, the return is reviewed by JDRF's Audit Committee of the Board of Directors with its outside tax advisors. Once approved, the return is distributed to all members of JDRF's Board of Directors for review and comment before it is filed with the Internal Revenue Service.”

“LINE 4A ($89,137,491) RESEARCH GRANTS JDRF has played a significant role in nearly every T1D therapeutic advance made in the last 50 years. Our funding supports more than 500 active T1D research grants in the United States and 21 other countries around the world including more than 150 grants in 2019 alone, plus 75 clinical trials. We leverage partnerships with academia, industry and clinicians to accelerate the most promising research opportunities. Our highest priority is developing cures for T1D and improving lives of those living with the disease today, including research in glucose control and prevention of T1D complications. The full impact of JDRF's research investment extends well beyond direct funding. Through advocacy and influence, JDRF drives funding from other sources into the T1D research and has helped secure passage of the Special Diabetes Program, putting more than $2.8 billion in federal funding toward T1D research over the last two decades. In addition, JDRF founded the JDRF T1D Fund (www.t1dfund.org). The wholly owned subsidiary of JDRF, the Fund is a venture philanthropy fund accelerating life-changing solutions to treat, prevent and cure T1D through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, pharma and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines to help people living with T1D or at risk of developing the disease. The T1D Fund invests in opportunities that drive our mission, with an exclusive focus on the best commercial opportunities. All funds go directly to support companies developing approaches to treat, prevent and cure T1D. In accordance with GAAP, $21.4MM of the T1D Fund's total investments as of June 30, 2019 are reflected in the Balance Sheet (Part X) and not included within the organization's research-related mission expense. The foundation's diversified research portfolio includes a focus on Curing T1D and Improving Lives. Curing T1D We face two key challenges in Curing T1D. We must prevent, stop or reverse: the loss of insulin-producing beta cells, and the immune systems attack on beta cells. JDRF is accelerating our work in Curing T1D by focusing on the two areas that have advanced dramatically over the last years: Beta Cell Therapies and Immune Therapies. Beta Cell Therapies: focus on replacing insulin-producing beta cells from outside sources and on internally regenerating and protecting existing beta cells. Through donor-funded research, we now know that when someone has T1D, their own body turns on itself, attacking and destroying the beta cells that create insulin. Understanding the role of beta cells -- was a breakthrough. If we can save beta cells, we can help cure T1D. Immune Therapies: focus on ways to keep the immune system from attacking and destroying beta cells, and to prevent the onset and advancement of T1D. Research has shown that immune therapies can interact with a persons immune system, training it to combat internal battles like cancer or autoimmune diseases like rheumatoid arthritis and T1D. While T1D remains one of the only major autoimmune diseases without an effective drug therapy, we know we are getting close. Improving Lives T1D brings with it daily struggles and stress that that make the challenges of living a healthy and long life with T1D very real. JDRF fights every day to advance research and technology that can reduce the burden of living with T1D and keep people as healthy as possible until we find cures. Specifically, we are striving to improve lives by driving research and work in Glucose Control Therapies and Complications Therapies which includes psychosocial well-being. Glucose Control Therapies: focus on helping those with T1D manage glucose levels and overall metabolic balance, including improved artificial pancreas technology, developing next-generation insulins and developing new drugs that”

“FORM 990- PART VI-SECT B, LINE 12C All officers, directors, key employees, board and committee members (both chapters and international boards) are required to sign a conflict of interest policy annually and disclose any conflicts. The Office of the President and CEO manages this process, and JDRF's internal audit department annually audits to ensure compliance. If any conflict does arise, the board members with the conflicts will recuse themselves from the meeting and/or vote.”

“Form 990, part x, lines 27-29: the fasb issued accounting standards update (asu) 2016-14 not-for-profit entities (topic 958), presentation of financial statements of not-for-profit entities, which among other things, changes how not-for-profit entities report net asset classes. The significant requirements of asu 2016-14 include reduction in the number of net asset classes from three to two: with donor restrictions (formerly reported as temporarily restricted net assets) and without donor restrictions (formerly reported as unrestricted net assets). The 2018 form 990, part x was not updated to reflect the changes in net asset class terminology; therefore, jdrf has reported net assets without donor restriction as unrestricted net assets and net assets with donor restriction as temporarily restricted net assets and permanently restricted net assets, as applicable.”